Annual Accounts Payable
$4.93 B
-$220.00 M-4.28%
31 December 2023
Summary:
Novartis AG annual accounts payable is currently $4.93 billion, with the most recent change of -$220.00 million (-4.28%) on 31 December 2023. During the last 3 years, it has fallen by -$477.00 million (-8.83%). NVS annual accounts payable is now -19.88% below its all-time high of $6.15 billion, reached on 31 December 2013.NVS Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$4.09 B
-$59.00 M-1.42%
30 September 2024
Summary:
Novartis AG quarterly accounts payable is currently $4.09 billion, with the most recent change of -$59.00 million (-1.42%) on 30 September 2024. Over the past year, it has increased by +$217.00 million (+5.61%). NVS quarterly accounts payable is now -33.52% below its all-time high of $6.15 billion, reached on 31 December 2013.NVS Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVS Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -4.3% | +5.6% |
| 3 y3 years | -8.8% | -12.4% |
| 5 y5 years | -11.3% | -12.5% |
NVS Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -11.3% | at low | -26.4% | +5.6% |
| 5 y | 5 years | -11.3% | at low | -26.4% | +5.6% |
| alltime | all time | -19.9% | +399.6% | -33.5% | +330.7% |
Novartis AG Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.09 B(-1.4%) |
| June 2024 | - | $4.15 B(+2.1%) |
| Mar 2024 | - | $4.06 B(-17.5%) |
| Dec 2023 | $4.93 B(-4.3%) | $4.93 B(+27.3%) |
| Sept 2023 | - | $3.87 B(-27.7%) |
| June 2023 | - | $5.35 B(-1.4%) |
| Mar 2023 | - | $5.43 B(+5.4%) |
| Dec 2022 | $5.15 B(-7.3%) | $5.15 B(+9.7%) |
| Sept 2022 | - | $4.69 B(-5.6%) |
| June 2022 | - | $4.97 B(-2.2%) |
| Mar 2022 | - | $5.08 B(-8.5%) |
| Dec 2021 | $5.55 B(+2.8%) | $5.55 B(+19.0%) |
| Sept 2021 | - | $4.67 B(-3.0%) |
| June 2021 | - | $4.81 B(-4.5%) |
| Mar 2021 | - | $5.04 B(-6.7%) |
| Dec 2020 | $5.40 B(-0.4%) | $5.40 B(+14.8%) |
| Sept 2020 | - | $4.71 B(-2.4%) |
| June 2020 | - | $4.82 B(-0.2%) |
| Mar 2020 | - | $4.83 B(-11.0%) |
| Dec 2019 | $5.42 B(-2.4%) | $5.42 B(+16.2%) |
| Sept 2019 | - | $4.67 B(-1.7%) |
| June 2019 | - | $4.75 B(+2.5%) |
| Mar 2019 | - | $4.64 B(-16.5%) |
| Dec 2018 | $5.56 B(+7.5%) | $5.56 B(+11.8%) |
| Sept 2018 | - | $4.97 B(-9.4%) |
| June 2018 | - | $5.49 B(+9.9%) |
| Mar 2018 | - | $4.99 B(-3.4%) |
| Dec 2017 | $5.17 B(+6.1%) | $5.17 B(+10.3%) |
| Sept 2017 | - | $4.68 B(-0.1%) |
| June 2017 | - | $4.69 B(+2.7%) |
| Mar 2017 | - | $4.57 B(-6.3%) |
| Dec 2016 | $4.87 B(-14.0%) | $4.87 B(+4.5%) |
| Sept 2016 | - | $4.66 B(-5.2%) |
| June 2016 | - | $4.92 B(+4.6%) |
| Mar 2016 | - | $4.70 B(-17.0%) |
| Dec 2015 | $5.67 B(+4.6%) | $5.67 B(+17.5%) |
| Sept 2015 | - | $4.83 B(-5.9%) |
| June 2015 | - | $5.13 B(+1.3%) |
| Mar 2015 | - | $5.06 B(-6.6%) |
| Dec 2014 | $5.42 B(-11.9%) | $5.42 B(+19.9%) |
| Sept 2014 | - | $4.52 B(-9.4%) |
| June 2014 | - | $4.99 B(-9.0%) |
| Mar 2014 | - | $5.49 B(-10.8%) |
| Dec 2013 | $6.15 B(+9.9%) | $6.15 B(+21.0%) |
| Sept 2013 | - | $5.08 B(+0.7%) |
| June 2013 | - | $5.04 B(+3.4%) |
| Mar 2013 | - | $4.88 B(-12.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $5.59 B(+12.1%) | $5.59 B(+21.8%) |
| Sept 2012 | - | $4.59 B(+0.1%) |
| June 2012 | - | $4.58 B(+2.2%) |
| Mar 2012 | - | $4.49 B(-10.1%) |
| Dec 2011 | $4.99 B(+4.2%) | $4.99 B(+13.6%) |
| Sept 2011 | - | $4.39 B(-5.5%) |
| June 2011 | - | $4.64 B(+3.3%) |
| Mar 2011 | - | $4.50 B(-6.1%) |
| Dec 2010 | $4.79 B(+19.3%) | $4.79 B(+20.1%) |
| Sept 2010 | - | $3.99 B(+13.6%) |
| June 2010 | - | $3.51 B(-1.5%) |
| Mar 2010 | - | $3.56 B(-11.2%) |
| Dec 2009 | $4.01 B(+18.2%) | $4.01 B(+22.5%) |
| Sept 2009 | - | $3.28 B(-1.3%) |
| June 2009 | - | $3.32 B(+1.8%) |
| Mar 2009 | - | $3.26 B(-3.9%) |
| Dec 2008 | $3.40 B(+12.5%) | $3.40 B(+17.0%) |
| Sept 2008 | - | $2.90 B(-10.7%) |
| June 2008 | - | $3.25 B(+8.1%) |
| Mar 2008 | - | $3.01 B(-0.4%) |
| Dec 2007 | $3.02 B(+21.4%) | $3.02 B(+10.8%) |
| Sept 2007 | - | $2.73 B(+8.6%) |
| June 2007 | - | $2.51 B(-2.6%) |
| Mar 2007 | - | $2.58 B(+3.5%) |
| Dec 2006 | $2.49 B(+26.8%) | $2.49 B(+17.7%) |
| Sept 2006 | - | $2.11 B(-3.8%) |
| June 2006 | - | $2.20 B(+13.4%) |
| Mar 2006 | - | $1.94 B(-1.3%) |
| Dec 2005 | $1.96 B(-2.9%) | $1.96 B(+10.6%) |
| Sept 2005 | - | $1.77 B(-9.8%) |
| June 2005 | - | $1.97 B(+6.6%) |
| Mar 2005 | - | $1.84 B(-8.8%) |
| Dec 2004 | $2.02 B(+21.3%) | $2.02 B(+28.8%) |
| Sept 2004 | - | $1.57 B(-3.8%) |
| June 2004 | - | $1.63 B(+2.1%) |
| Mar 2004 | - | $1.60 B(-4.1%) |
| Dec 2003 | $1.67 B(+31.5%) | $1.67 B(+27.3%) |
| Sept 2003 | - | $1.31 B(-8.7%) |
| June 2003 | - | $1.43 B(+11.3%) |
| Mar 2003 | - | $1.29 B(+1.7%) |
| Dec 2002 | $1.27 B(+15.9%) | $1.27 B(+33.4%) |
| Sept 2002 | - | $949.00 M(-7.6%) |
| June 2002 | - | $1.03 B(-6.0%) |
| Dec 2001 | $1.09 B(+10.8%) | $1.09 B(+10.8%) |
| Dec 2000 | $986.00 M(-20.4%) | $986.00 M |
| Dec 1999 | $1.24 B(+10.8%) | - |
| Dec 1998 | $1.12 B | - |
FAQ
- What is Novartis AG annual accounts payable?
- What is the all time high annual accounts payable for Novartis AG?
- What is Novartis AG annual accounts payable year-on-year change?
- What is Novartis AG quarterly accounts payable?
- What is the all time high quarterly accounts payable for Novartis AG?
- What is Novartis AG quarterly accounts payable year-on-year change?
What is Novartis AG annual accounts payable?
The current annual accounts payable of NVS is $4.93 B
What is the all time high annual accounts payable for Novartis AG?
Novartis AG all-time high annual accounts payable is $6.15 B
What is Novartis AG annual accounts payable year-on-year change?
Over the past year, NVS annual accounts payable has changed by -$220.00 M (-4.28%)
What is Novartis AG quarterly accounts payable?
The current quarterly accounts payable of NVS is $4.09 B
What is the all time high quarterly accounts payable for Novartis AG?
Novartis AG all-time high quarterly accounts payable is $6.15 B
What is Novartis AG quarterly accounts payable year-on-year change?
Over the past year, NVS quarterly accounts payable has changed by +$217.00 M (+5.61%)